Failure of chemotherapy to prolong life in patients with metastatic prostate cancer who have failed androgen deprivation.
Using historical controls, we analyzed the effect of chemotherapy on survival of patients with metastatic prostate cancer who failed androgen deprivation. The survival of 178 patients with metastatic prostate cancer who receive palliation only after failing hormonal therapy was compared with the survival of 27 patients who received chemotherapy on NPCP Protocol 1500. Survival was measured from the initiation of androgen deprivation. The mean survival after chemotherapy was 8.4 months which was slightly less than the group receiving palliation only. At this time, chemotherapy has not been able to improve survival in patients with metastatic prostate cancer.